Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A stock certificate on a wooden table with a plant in the background.

Jun 8, 2026

A Look At SELLAS Life Sciences Group (SLS) Valuation After Arbitration And Phase 3 Regal Trial Hopes

SELLAS Life Sciences Group (SLS) is currently under scrutiny due to its arbitration with 3D Medicines and the anticipated results from its Phase 3 Regal trial. These factors, combined with its cash position, have contributed to a notable uptick in investor interest.The company's stock has seen significant gains, with a 30-day return of 64.3% and a year-to-date increase of 89.2%. This surge in share price reflects growing investor confidence, particularly as they await the outcomes of arbitration
DNA helix and data graph

Jun 8, 2026

TEM: Tempus leverages integrated data and AI to drive diagnostics growth and pharma partnerships

Tempus is harnessing the power of integrated data and artificial intelligence to enhance its diagnostics capabilities and forge strategic partnerships within the pharmaceutical industry. The company is making significant strides by combining molecular and clinical data at scale, which is pivotal for its growth in diagnostics. Increasing sequencing costs and recent FDA approvals are contributing positively to its revenue streams. Furthermore, Tempus's partnerships and its proprietary datasets are
A cancer cell viewed through a microscope in a dimly lit lab setting.

Jun 8, 2026

Beating Cancer Plan: Von der Leyen calls for equal access to care and faster innovation

European Commission President Ursula von der Leyen has emphasized the EU's commitment to combating cancer, marking World Brain Tumour Day with a call for equitable access to care and accelerated innovation through the Beating Cancer Plan.In her address, von der Leyen highlighted the alarming statistics surrounding cancer in Europe, noting that approximately 2.7 million new cancer diagnoses occur each year, including 42,000 brain tumor cases. She underscored the importance of prevention, stating
Minimalist illustration of a pill bottle and healthcare professional in dark colors with lime accents.

Jun 8, 2026

How AI is rewriting customer engagement in pharma

The integration of AI in customer engagement within the pharmaceutical industry is reshaping how companies interact with healthcare professionals and patients. Despite the potential benefits, many commercial leaders express frustration over the lack of tangible results from AI initiatives, emphasizing the need for meaningful conversations in an increasingly complex healthcare landscape.Executives are grappling with the challenge of enhancing patient outcomes amid a complicated and constrained sy
A minimalist representation of a dollar sign split in half, symbolizing business divestiture.

Jun 8, 2026

How Investors May Respond To Revvity (RVTY) Divesting Its China Immunodiagnostics Business

Revvity's recent decision to divest its immunodiagnostics business in China, which contributed approximately 6% to its revenue, reflects a strategic pivot towards more lucrative sectors within life sciences and diagnostics. This move comes on the heels of the company's first-quarter results, showcasing a 6% pro forma organic growth and a robust 24% adjusted operating margin across its business segments.The divestiture aims to alleviate challenges posed by regulatory and cash flow constraints in
A vial of SKYTROFA and a syringe in a dimly lit laboratory setting.

Jun 8, 2026

Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness

Ascendis Pharma (NasdaqGS:ASND) is currently experiencing a decline in its stock price, which has fallen approximately 4% over the past week and 12% over the last month, settling at $210.45. This downturn continues a trend of underperformance, with a year-to-date return down 14.24%, despite ongoing advancements in its TransCon endocrinology and oncology portfolio.The company, valued at around $13.1 billion, specializes in TransCon-based therapies, including SKYTROFA and YORVIPATH, and is explori
A petri dish with a biological sample in a dimly lit lab setting.

Jun 8, 2026

Biological Expertise and Iterative Speed Replace AI Software as Primary Biotech Competitive Advantages

The biotechnology sector is witnessing a significant shift where biological expertise and rapid iterative development are becoming more crucial than AI software tools in maintaining competitive advantages.The integration of artificial intelligence in drug discovery is evolving the competitive landscape for biotech firms. As AI-driven platforms become commonplace, the focus is shifting from software capabilities to the selection of biological targets and the validation processes that follow. Indu
A minimalist illustration of a test tube representing oncology diagnostics.

Jun 8, 2026

How Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics

Agilent Technologies is making significant strides in enhancing its AI-enabled lab solutions and oncology diagnostics, as evidenced by its recent quarterly performance and strategic collaborations.In the latest reporting period, Agilent experienced an uptick in sales and earnings, prompting an upward revision of its fiscal 2026 revenue forecast to between $7.39 billion and $7.49 billion. This growth is complemented by the FDA's expanded approval of its PD-L1 IHC 22C3 pharmDx diagnostic and the l
Hospital bed in a municipal healthcare setting

Jun 8, 2026

Mumbai: Ashish Shelar asks BMC to modernise Mumbai healthcare

Maharashtra Minister Ashish Shelar has urged the Brihanmumbai Municipal Corporation (BMC) to modernize Mumbai's public healthcare system through the integration of advanced medical technologies and comprehensive administrative reforms.During a recent high-level meeting, Shelar emphasized that enhancing the quality of healthcare should be the BMC's primary focus. He called for a thorough review of current healthcare processes to identify inefficiencies and develop a strategic plan aimed at improv
Flat illustration of an analyzer system in a minimalist style

Jun 8, 2026

Stratec SE stock (DE000STRA555): Diagnostic supplier in focus after latest trading update

Stratec SE, a specialized player in in-vitro diagnostics, remains a focal point for investors following its latest trading updates amidst changing market dynamics.Stratec SE operates primarily in the production of automation solutions and analyzer systems tailored for the life sciences and diagnostics sectors. As it navigates the post-pandemic landscape, the company has been actively updating stakeholders on its order situation and profitability amid rising cost pressures in the medtech supply c
A minimalist illustration of a brain and neurons representing AI in diagnostics.

Jun 8, 2026

How new AI tool could prevent diagnostic mistakes

A recent study has introduced an AI tool aimed at enhancing diagnostic accuracy for Alzheimer's disease and related dementias, indicating a significant advancement in clinical practices.The Automated Imaging Differentiation of Dementia (AIDD) tool leverages advanced imaging and AI to effectively differentiate between Alzheimer’s disease and dementia with Lewy bodies. This distinction is critical, as the two forms of dementia exhibit different symptoms and require varied treatment approaches. Mis
A stack of coins on research papers in a university office setting.

Jun 8, 2026

Creator Fund Raises $56M to Back Europe’s Innovators

Creator Fund has raised €48.8 million ($56 million) to invest in early-stage European technology, focusing on university researchers and PhD candidates before they formally pitch their ideas.The fund, which closed with significant backing from KfW Capital, aims to address the gap between academic innovation and venture capital. Founded in 2019 by Jamie Macfarlane, Creator Fund operates on the premise that Europe is home to groundbreaking scientific research that often goes unnoticed by tradition